Publications & Resources

MLMIC’s insured neurosurgeons are encouraged to review resources that will provide an understanding of the unique risks associated with the specialty and reduce the likelihood of exposure to medical professional liability.

MLMIC encourages policyholders to review these important Risk Management Checklists on opioid management, including guidance on managing patients with chronic pain and managing drug seeking patients.

Physicians can now turn to new guidance when advising diabetic patients on how to use modern glucose monitoring devices to exercise safely.

The U.S. Food and Drug Administration has granted Eli Lilly and Company an emergency use authorization for bamlanivimab to treat mild-to-moderate COVID-19 in adult and pediatric patients.

The coronavirus continues to affect our daily lives, but there is light at the end of the tunnel. Take a look at our FAQs for dentists about the COVID-19 vaccine, trials and what it means for dental practices.

The U.S. Food and Drug Administration has approved the antiviral drug remdesivir, sold as Veklury, to treat COVID-19 patients who meet specific criteria.

Dental amalgam is “durable, safe and effective” despite containing mercury, the American Dental Association reaffirmed, responding to a recent statement by the Food and Drug Administration.

The FDA cautions that a number of websites are illegally selling unauthorized opioids that may be counterfeit, contaminated, expired or otherwise unsafe.

Dentists could potentially find themselves facing liability claims from patients who allege they contracted COVID-19 while receiving treatment at a dentist’s office, but whether that lawsuit will be successful is another question.

The American Dental Association emphasized that dentists, as essential health care workers, should be among those groups allowed early access to the COVID-19 vaccine when it becomes available.